Neuraltus Pharmaceuticals is a technology company.
Neuraltus Pharmaceuticals has raised $42.0M across 3 funding rounds.
Neuraltus Pharmaceuticals has raised $42.0M in total across 3 funding rounds.
Neuraltus Pharmaceuticals has raised $42.0M in total across 3 funding rounds.
Neuraltus Pharmaceuticals's investors include Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company focused on developing innovative therapeutics for neurodegenerative diseases. It builds drug candidates aimed at addressing serious neurological conditions, serving patients with unmet medical needs in this challenging therapeutic area. The company has demonstrated growth momentum through advancing multiple clinical trials and building a robust drug pipeline targeting neurodegeneration[1][2][3][4].
Founded in 2004 and headquartered in San Bruno, California, Neuraltus Pharmaceuticals was established by founders with expertise in neuroscience and drug development. The idea emerged from the need to create effective treatments for neurodegenerative disorders, a field with significant unmet demand. Early traction came from progressing promising drug candidates into clinical development, positioning the company as a focused innovator in neurological therapeutics[2][4].
Neuraltus rides the growing trend of precision medicine and targeted therapies for neurological disorders, a field gaining momentum due to aging populations and increasing prevalence of diseases like Alzheimer’s and Parkinson’s. The timing is critical as advances in neuroscience, biomarker identification, and drug delivery technologies converge to enable new treatment possibilities. Market forces such as rising demand for effective neurotherapeutics and increased investment in biotech innovation work in Neuraltus’s favor. The company contributes to the broader ecosystem by pushing forward novel approaches that could redefine neurodegenerative disease treatment paradigms[1][3][4].
Looking ahead, Neuraltus Pharmaceuticals is poised to continue advancing its clinical pipeline, potentially bringing new therapies closer to market approval. Trends shaping its journey include breakthroughs in neurobiology, regulatory support for innovative neurological drugs, and growing patient advocacy for better treatments. As it matures, Neuraltus’s influence may expand through partnerships, licensing, or eventual commercialization, reinforcing its role as a key player in neurodegenerative disease therapeutics. This trajectory ties back to its founding mission of addressing critical unmet needs in neurological health with cutting-edge science[1][2][3][4].
Neuraltus Pharmaceuticals has raised $42.0M across 3 funding rounds. Most recently, it raised $15.0M Venture Round in May 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2016 | $15.0M Venture Round | Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | |
| Jan 1, 2012 | $10.0M Series B | Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | |
| Mar 1, 2009 | $17.0M Series A | Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners |